Sedation of Ventilated Patients with Heart Failure

Sedation for patients undergoing noninvasive ventilation (NIV), particularly with heart failure, requires significant expertise. It is a strategy within a bundle of care aimed at improving tolerance to this essential procedure. Non-pharmacological interventions such as optimizing the interface, correcting patient-ventilator asynchronies, and ensuring comfortable positioning should precede sedation where applicable. Sedation is indicated if discomfort persists despite these strategies, or in cases of hypoxic delirium or untreatable delirium-related dementia. For heart failure patients, careful assessment of hemodynamic status is crucial, as this can limit medication choices, and certain conditions like ischemic heart disease are contraindications for some drugs. Medication selection depends on the prevailing issue (pain, dyspnea, or agitation/delirium). Dexmedetomidine is often the first choice for agitation/delirium due to its ventilatory profile and low delirium rate, but its hypotensive effect requires management. Ketamine is effective, especially in hypotensive patients, preserving airway reflexes and supporting hemodynamics, though contraindicated in severe hypertension or ischemic heart disease. Combining Ketamine and Dexmedetomidine (KETADEX) can optimize their safety profiles, offsetting hypotension and reducing delirium. The goal is the lowest sedation level for tolerance, avoiding excessive respiratory depression.